Ramping up in-house drug development, API maker BrightGene bags $80M round led by Sequoia China
A Chinese biotech armed with an arsenal of APIs and finished dosage forms of specialty generic drugs has just raised $80 million (RMB$550 million) to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
